Key clinical point: Trastuzumab deruxtecan demonstrated a favorable benefit-risk profile in patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC) who were refractory or resistant to trastuzumab emtansine and had scarce treatment options.
Major finding: The median progression-free survival was significantly prolonged in the trastuzumab deruxtecan vs physician’s choice treatment group (17.8 vs 6.9 months; hazard ratio 0.36; P < .0001). No new safety signals were reported for trastuzumab deruxtecan.
Study details: Findings are from the phase 3, DESTINY-Breast02 trial including 608 patients with HER2+ metastatic BC who were refractory or resistant to trastuzumab emtansine and were randomly assigned to receive trastuzumab deruxtecan or treatment of physician's choice.
Disclosures: This study was funded by Daiichi Sankyo and AstraZeneca. Five authors declared being current or former employees of Daichi Sankyo, and two authors declared owning stock options in AstraZeneca or Daiichi Sankyo. The other authors reported ties with several sources.
Source: Andre F et al. Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): A randomised, open-label, multicentre, phase 3 trial. Lancet. 2023 (Apr 19). Doi: 10.1016/S0140-6736(23)00725-0